Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Smoldering Multiple Myeloma 3 Monoclonal Gammopathy of Undetermined Significance 3 Stomach Neoplasms 2 Prostatic Neoplasms 2 Multiple Myeloma 2 Uterine Cervical Dysplasia 1 Thrombocythemia, Essential 1 Rectal Neoplasms 1 Psychological Well-Being 1 Primary Myelofibrosis 1 Polycythemia Vera 1 Polycystic Ovary Syndrome 1 Neurofibromatosis 1 1 Neoplasms 1 Myelodysplastic Syndromes 1 Motor Activity 1 Lung Neoplasms 1 Joint Diseases 1 Gastritis, Atrophic 1 Esophageal Neoplasms 1 Colonic Neoplasms 1 Castration Sensitive Prostate Cancer 1 Breast Neoplasms 1 Arthralgia 1

Interventions

pembrolizumab 90 Blood Specimen Collection 41 Cyclophosphamide 37 Bevacizumab 36 Nivolumab 35 Standard of Care 32 Carboplatin 31 Surveys and Questionnaires 29 Paclitaxel 27 atezolizumab 25 Exercise 25 Pemetrexed 24 Gemcitabine 24 Cisplatin 23 Fluorouracil 22 Radiotherapy 20 Leucovorin 20 Dexamethasone 20 Docetaxel 19 Oxaliplatin 18 Rituximab 16 Irinotecan 16 Cetuximab 16 dostarlimab 15 Drug Therapy 15 Doxorubicin 15 Ipilimumab 14 Biopsy 14 130-nm albumin-bound paclitaxel 14 fludarabine 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Curcumin × 1 year × Clear all

NCT06626230 2026-05-18

Safety of Anal Curcumin

Emory University

Phase 1 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡